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It is widely recognized that exposure to combinations or mixtures of chemicals may result in highly exaggerated toxicity even though the individual
chemicals might not be toxic. Assessment of risk from exposure to combinations of chemicals requires the knowledge of the underlying mecha-
nism(s). Dietary exposure to a nontoxic dose of chlordecone (CD; 10 ppm, 15 days) results in a 67-fold increase in lethality of an ordinarily inconse-
quential dose of CCI4 (100 pl/kg, ip). Toxicity of closely related CHCI3 and BrCCI3 is also enhanced. Phenobarbital (PB, 225 ppm, 15 days) and mirex
(10 ppm, 15 days) do not share the propensity of CD in this regard. Exposure to PB + CCI4 results in enhanced liver injury similar to that observed
with CD, but the animals recover and survive in contrast to the greatly amplified lethality of CD + CC14. Investigations have revealed that neither
enhanced bioactivation of CCI4 nor increased lipid peroxidation offers a satisfactory explanation of these findings. Additional studies indicate that
exposure to a low dose of CC14 (100 pl/kg, ip) results in limited injury, which is accompanied by a biphasic response of hepatocellular regeneration (6
and 36 hr) and tissue repair, which enables the animals to recover from injury. Exposure to CD + CCI4 results in suppressed tissue repair owing to an
energy deficit in hepatocytes as a consequence of excessive intracellular influx of Ca2, leading initially to a precipitous decline in glycogen and ulti-
mately to hypoglycemia. Supplementation of cellular energy results in restoration of the tissue repair and complete recovery from the toxicity of CD
+ CCI4 combination. In contrast, only the early-phase hepatic tissue repair (6 hr) is affected in PB + CCI4 treatment, but this is adequately compen-
sated for by a greater stimulation of tissue repair at 24 and 48 hr resulting in recovery from liver injury and animal survival. A wide variety of addi-
tional experimental evidence confirms the central role of stimulated tissue repair as a decisive determinant of the final outcome of liver injury
inflicted by CC14. For instance, a 35-fold greater CC14 sensitivity of gerbils compared to rats is correlated with the very sluggish tissue repair in ger-
bils. These findings are consistent with a two-stage model of toxicity, where tissue injury is inflicted by the well described "mechanisms of toxic-
ity," but the outcome of this injury is determined by whether or not sustainable tissue repair response accompanies this injury. These findings
impact significantly on our ability to predict the ultimate outcome of toxic injury and form a firm basis for additional mechanism-driven investigations
into the endogenous tissue repair response evoked by tissue injury. These concepts will enhance our ability to fine-tune the tools of risk assess-
ment such as animal-to-man extrapolation and prediction of ultimate outcome of toxic injury. -Environ Health Perspect 102(Suppl 9):139-149
(1994)
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Introduction
From a perspective of public health, a
major toxicological issue is the possibility
of unusual toxicity due to interaction of
two or more toxic chemicals at individually
harmless levels upon environmental or
occupational exposures. While some labo-
ratory models exist for such interactions
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involving two chemicals, progress in this
area has suffered for want of models where
the two interactants are individually non-
toxic. Toxicities resulting from exposure to
more than two chemicals at individually
nontoxic doses are ofgreater interest since
this exposure scenario is most common.
One such model is available, where prior
exposure to nontoxic levels ofthe pesticide
Kepone (Chlordecone) results in a 67-fold
amplification of CC14 lethality in rats
(Table 1). The mechanism of this remark-
able interactive toxicity is of interest in the
assessment ofrisk from exposure to combi-
nations ofchemicals.
AmplifiedToxicityofCC14by
Chlordecone
Prior exposure to a nontoxic level of
chlordecone (10 ppm in diet for 15 days)
results in a marked amplification of CC14
hepatotoxicity (1-3) and lethality (3-5).
Neither the close structural analogs of
chlordecone, mirex and photomirex, nor
phenobarbital (Figure 1), exhibit this prop-
erty (2,3). Plaa and associates (6,7) have
demonstrated the capacity ofchlordecone
to potentiate CHC13 hepatotoxicity in
mice. These observations have been
extended to demonstrate that, in addition
to the hepatotoxic effects, the lethal effect
of CHC13 is also potentiated by exposure
to 10 ppm dietary chlordecone (8) (Table
2) and that this is also associated with sup-
pressed repair of the liver tissue (9).
Chlordecone also potentiates the hepato-
toxicity and lethality of BrCCl3 (10,11).
While the toxicity of these closely related
halomethanes is potentiated by such low
levels ofchlordecone (Figure 2), the toxic-
ity ofstructurally and mechanistically dis-
similar compounds (Figure 3, Table 3) is
not potentiated (12) except after exposure
to high levels of chlordecone (13). This
remarkable capacity to potentiate
halomethane hepatotoxicity does not
appear to be related to chlordecone-
induced cytochrome P450 or associated
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Table 1. Amplification of lethal effects of several
halomethanes by dietary exposure of rats to subtoxic
contaminants.
Dietary 48 hr LD50 Increase in
pretreatment Halomethane ml/kg toxicity-fold
Female rats
Control CCI4 1.25
Chlordecone
10 ppm CCI4 0.048a 26
Male rats
Control CCI4 2.8
Chlordecone
10 ppm CCI4 0.042a 67
Phenobarbital
225 ppm CCI4 1.7 1.6"
Control BrCCI3 0.119
Chlordecone
10 ppm BrCCI3 0.027a 4.5
aHighly significant compared to the respective solvent
control: bNot significant at p < 0.05. Mehendale (1):
reproduced by permission of MedicalHypotheses.
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Figure 1. Structures of chlordecone, mirex, pho-
tomirex, and phenobarbital. Chlordecone (Kepone)
amplifies the toxicity of halomethanes closely related
to CCI4. Despite being close structural analogues of
chlordecone, mirex and photomirex do not possess this
propensity. Phenobarbital, a commonly employed drug
in interaction studies at high doses, does increase liver
injury of CCI4, but this enhanced liver injury is inconse-
quential to animal survival and health, since phenobar-
bital-treated animals are able to recover from liver
injury.
enzymes (2,5,14), enhanced bioactivation
ofCC14 (12,15-18), increased lipid peroxi-
dation (2,12,13), or decreased glutathione
(19). Several candidate mechanisms were
considered carefully in experiments
designed to verify and were found inade-
quate; additional experiments revealed a
novel mechanism (Table 4).
Mechanism ofChlordecone-amplified
ToxicityofCC14
These findings led to some very basic stud-
ies concerning the progression ofthe hepa-
totoxicity during a time-course following
CC14 administration to either normal
or chlordecone pretreated rats. The
histochemical and histomorphometric
experiments revealed that suppressed hepa-
tocellular regeneration and tissue repair
(1,2,20,21) might explain the remarkable
amplification of CC14 toxicity by prior
exposure to chlordecone. Similar time-
course studies on Ca2+ levels in the liver
mitochondria, microsomes, and cytosol
fractions (22,23) revealed a possible associ-
ation of increased Ca2+ accumulation and
suppressed hepatocellular regeneration.
Despite some reports that chlordecone
interferes with Ca2+ uptake mechanisms in
extrahepatic tissues (24), chlordecone
alone does not cause disruption ofhepato-
cellular Ca2+ (25) even at toxic doses.
Chlordecone + CC14 interaction results in
remarkably increased intracellular Ca2+
(22-26). Recent studies have also shown a
significant activation ofphosphorylase a, a
finding consistent with the precipitous
depletion ofglycogen (21,27-29) and ATP
(27-29). Based on several lines ofexperi-
mental evidence, a hypothesis was pro-
posed (1) for the mechanism of the
interactive toxicity of chlordecone and
CC14.
Stimulation ofTissue Repair as a
Hormetic ResponsetoTissueInjury
First, it became necessary to hypothesize
the mechanism for why an ordinarily non-
toxic dose of CC14 is nontoxic (2). Figure
4 illustrates the mechanism of recovery
from limited liver injury observed after the
administration ofa low dose ofCC14 alone.
Within 6 hr after the administration of a
low dose of CC14, limited hepatocellular
necrosis accompanied by ballooned cells
and steatosis inflicted by the same widely
accepted mechanisms ofCC14 bioactivation
followed by lipid peroxidation occurs. By
mechanisms yet to be understood, simulta-
neously the liver tissue responds by stimu-
lating hepatocellular regeneration (20,21).
Most interestingly, one burst ofhepatocel-
lular division is evident at 6 hr, even
though centrilobular necrosis only begins
to manifest at that time. A;lthough the mol-
ecular events responsible for the stimula-
tion of hepatocellular division have not
been explored, glycogen, the principal form
of hepatic energy resource, is mobilized
prior to cell division (20,21). Glycogen
levels are restored after cell division has
been adequately stimulated (20,21). The
limited hepatocellular necrosis enters the
progressive phase between 6 and 12 hr
(20,21,30,31), while the hepatocellular
regeneration and tissue healing processes
continue. By 24 hr, no significant liver
injury is evident. These observations indi-
cate that stimulation of hepatocellular
regeneration is a protective response ofthe
liver, occurs very early after the administra-
tion a low dose of CC14, and leads to
replacement ofdead cells, thereby restoring
the hepatolobular architecture (2,32,33).
Furthermore, this remarkable biological
event results in another important protec-
tive action. It is known that newly divided
liver cells are relatively resistant to toxic
chemicals (34-38). Therefore, in addition
to the restoration of the hepatolobular
architecture by cell division, by virtue of
the relatively greater resistance of the new
cells, the liver tissue is able to overcome the
imminence of greater injury during the
progressive phase (6-12 hr), preventing the
spread of injury on the one hand, and
Table 2. Amplification of lethal effects of halo-
methanes by dietary exposure of mice to subtoxic
contaminants.
Dietary 48 hr LD50 Increase in
pretreatment Halomethane ml/kg toxicity-fold
Male mice
Control CHCI3 0.67
Chlordecone
10 ppm CHCI3 0.16a 4.2
Mirex
10 ppm CHCI3 0.70 No change
Phenobarbital
225 ppm CHCI3 0.70 No change
aSignificantly different at p. 0.05. Mehendale (1):
reproduced by permissson of MedicalHypotheses.
Table 3. Specificity of potentiation of halomethane toxicity bychlordecone.
Compound Potentiation Reference
CHCI3 yes Hewitt et al. (6);
Purushotham et al. (8)
CCI4 yes Mehendale (2);
Curtis et al. (3)
CBrCI3 yes Agarwal and Mehendale (10)
Klingensmith and Mehendale (11)
CHBr3 no Mehendale (2)
CBr4 no Mehendale(2)
CCI2CHCI no Mehendale and Lockhart( 12)
Bromobenzene no Mehendale and Lockhart(12)
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e administered
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ture during and after the progressive phase
ofinjury (30,31,39,40). Relative resiliency
of the newly divided cells at this critical
time frame, as the animal continues to
e animal (2). At exhale the remaining CC14, is an added
and onwards), critical defense mechanism easily available
been eliminated through cell division.
eventing addi- Administration ofthe same low dose of
,ontinued cellu- CC14 to animals maintained on food conta-
iis time period minated with low doses of chlordecone
ws for complete results in initial injury by the same mecha-
)bular architec- nisms of bioactivation of CC14 and lipid
peroxidation (Figure 4). The liver injury in
Br this case is slightly greater by virtue of
approximately doubled rate of bioactiva-
Cl - C C1 tion of CC14 in livers of animals pre-
Cl exposed to chlordecone (2,14,33). The
motrichloromethane liver injury thus initiated, enters the pro-
gressive phase between 6-12 hr and this
phase is accelerated in the absence oftissue
repair mechanisms (20,21,30,31,39,40).
The highly unusual amplification ofCC14
toxicity relates to the suppression of the
initial hepatocellular regeneration, other-
wise ordinarily stimulated by CC14 within
achloride, bromotri- 6 hr (Figure 4).
examples of halo- The mechanism responsible for the
ty and lethality of abrogation of this hormetic response of
fied bychlordecone. stimulated cell division is of significant
interest. Substantial experimental observa-
tions indicate that a lack ofhepatocellular
Br energy leads to failure of cell division.
Under conditions ofincreased hepatocellu-
0l lar injury, mobilization ofhepatic glycogen
is initiated in order to stimulate hepatocel- Bromobenzene lular division (21-26). Insufficient energy
at a time ofincreased demand for cellular
H H energy (augmented need for extrusion of
extracellular Ca2+ from the cells, protection Br-C-C-a against free-radical mediated injury, and so
Br Cl forth), incapacitates the hepatocytes. As a
result, stimulation ofcell division, which
modichloromethane normally occurs after the administration of
hloroethylene, bro- a low dose ofCC14, cannot occur. The fail-
modichloromethane. ure of cell division has two important
potentiated by prior implications: first, hepatolobular structure
,cone. cannot be restored; second, unavailability
of newly divided, relatively resistant cells
Table 4. Specificity of potentiation of halomethane toxicity by chlordecone.
Mechanism Role in amplification
Enhanced bioactivation of Increased infliction of injury
halomethanes Only stage oftoxicity is increased
Increased lipid peroxidation Not known or none
Estrogenic property of chlordecone None
Increased Ca2+ accumulation Perturbed cellular biochemistry and ablation
Precipitous glycogenolysis and loss ofATP of hormetic mechanisms
Suppressed hepatocellular regeneration Injury becomes irreversible
and unabated progression to due to ablation ofthe early-phase
stage 11 oftoxicity hormesis
predisposes the liver to a permissive contin-
uation ofliver injury during the progressive
phase (6-12 hr and beyond) (1,2,26,33,
41,42). Permissively progressive injury
continues unabatedly as a consequence of
the mitigated tissue repair mechanisms,
leading to massive hepatic failure (1,4,5,
10), followed by animal death (1,41-44).
The mechanism underlying a rapid and
precipitous decline in cellular ATP is of
considerable interest. Many studies have
shown a biphasic increase in hepatocellular
Ca2+ levels in CC4 toxicity (23). The
unusual aspect ofexcessive Ca2+ accumula-
tion observed in livers treated with the
chlordecone + CCI4 combination is that it
occurs at a dose of CC14 not ordinarily
associated with the causation ofincreased
CC14 alone Chlordecone + CCI4
(100 pl/Kg) (10 ppm + 100 pI/Kg)
*
Normal Livert
Bloactivation, LIpid Slightly
Normal Peroxidation Increased
I Slightly
Limited Liver Damage Greater
Regeneration
Resiliency of
new cells
Hepatolobular
Restoration
Regression
of injury
Recovery
I(6h)
U
No
Regeneration
Lack of
Resistant Cells
Lack of Hepatolobular
Restoration
Progressive Injury
Liver Failure-Death
Figure 4. Proposed mechanism forthe highly amplified
interactive toxicity of chlordecone + CCI4. The scheme
depicts the concept of suppressed hepatocellular
regeneration, simply permitting what is normally lim-
ited liver injury caused by a subtoxic dose of CCI4 to
progress in the absence of hepatolobular repair and
healing mechanisms stimulated by the limited injury.
The limited hepatotoxicity from a low dose of CCI4 is
normally controlled and held in check owing to the
hepatocellular regeneration and hepatolobular healing.
The chlordecone + CCI4 combination treatment results
in unabated progression of injury owing to lack of tis-
sue repair obtunded due to lack of cellular energy.
These events lead to complete hepatic failure, culmi-
nating in animal death. Ongoing studies indicate that a
very similar mechanism is responsible for the amplifi-
cation of CHCI3 and BrCCI3 toxicity by chlordecone.
From Mehendale (1); reproduced with permission of
MedicalHypotheses.
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intracellular Ca2+. Furthermore, chlorde-
cone alone, even at a dose 10-fold higher
than used in the interaction studies, does
not increase hepatocellular Ca2+ (22,25).
Although in vitro studies with cellular
organelles have been employed to speculate
that the failure of organelle Ca2+ pumps
leads to increased cytosolic Ca2+ levels, our
studies indicate that at no time-point do
these organelles contain decreased Ca2+
(23,33). Indeed, the only sig-ificant
change observed with regard to organelle
Ca2+ is increased Ca2+ in the organelles in
association with increased liver jury
(33,41). Therefore, there is no in vivo evi-
dence for decreased Ca2+ content in the
organelles, which is in contradiction to the
predictions from the in vitro studies in
which organelle incubations were em-
ployed tostudyCa2+ uptake (26,27).
The primary mechanism leading to a
highly amplified toxicity is the failure on
CC14 alone Phenobarbital + CC,4
(100 PI/Kg) (225ppm + 100 pi/Kg)
Normal Liver
Normal Bioactivation, Lipid
Peroxidation
Limited I
Necrosis Liver Damage
3-Fold
increase
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new cells
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Figure 5. Proposed mechanism for phenobarbital-
induced potentiation of CCI4-hepatotoxicity in the
absence of increased lethality. Normal liver response
to a low-dose CC14 injury is not abrogated by pheno-
barbital + CC14 interaction. Instead, the early phase of
cell division is postponed from the normal 6 to 24 hr.
Enhanced putative mechanisms such as increased
bioactivation of CC4 and resultant increased lipid per-
oxidation are responsible for the increased infliction of
stage 1 injury. Because hepatocellular regeneration
and tissue repair processes continue albeit a bit later
than normal, these hormetic mechanisms permittissue
restoration resulting in recovery from the enhanced
liver injury. This mechanism explains the remarkable
recovery from phenobarbital-induced enhancement of
CCI4 liver injury. Despite a remarkably enhanced liver
injury by phenobarbital, this is of no real consequence
to the animal's survival because depletion of cellular
energy does not occur with this interaction, which per-
mits hormetic mechanisms to restore hepatolobular
architecture resulting in complete recovery.
the part ofthe biological events leading to
hepatocellular division. Increased accumu-
lation ofextracellular Ca2+ (23) during the
progressive phase ofliver injury would be
consistent with the significant loss of bio-
chemical homeostasis in hepatocytes
(Figure 4). Earlier histomorphometric (21)
as well as biochemical studies (28,29,33,
41) have shown that glycogen levels drop
very rapidly after CCl4 administration to
chlordecone treated animals. Increased
cytosolic Ca2+ (27) would be expected to
result in activation of phosphorylase b to
phosphorylase a, the enzyme responsible
for glycogenolysis. Phosphorylase a activity
(26,27) and precipitous glycogenolysis
(20,21,23,27) are observations consistent
with the rapid depletion ofcellular energy
(27) on the one hand, and irreversible in-
crease in cytosolic Ca2+ (26) on the other.
An intriguing aspect of the experimen-
tal framework leading to the proposed
mechanism is the observation that pheno-
barbital, even at significantly higher doses
(225 ppm in the diet for 15 days) does not
potentiate the lethal effect of CC14.
Although histopathological parameters of
liver injury such as hepatocellular necrosis
and ballooned cell response are indicative
ofsignificantly enhanced hepatotoxicity by
phenobarbital, ifthe animals are left alone,
this injury does not progress to significantly
increased lethality. Hepatic microsomal
cytochrome P450 is approximately doubled
by prior dietary exposure to 225 ppm PB
and the bioactivation of CC14 is tripled
(2,14), and these indicators are consistent
with the enhanced initiation ofliver injury
(Stage I of toxicity) measured by histo-
pathology, elevation of serum transami-
nases, or hepatic function. Nevertheless,
the liver injury neither progresses in an
accelerated fashion nor is irreversible, as
indicated by the reversal of liver injury
accompanied by animal survival (2,4,31).
Figure 5 illustrates the proposed mecha-
nism for phenobarbital-enhanced CC14
liver injury, which is not associated with
increased lethality. Induction ofhepatomi-
crosomal cytochrome P450 results in
approximate tripling ofCC14 bioactivation
and increased lipid peroxidation (2,14).
Enhanced liver injury is consistent with
these observations (Figure 5). It should be
recalled that the liver is normally able to
respond by stimulation of hepatocellular
regeneration after a low dose of CC14
within 6 hr (Figure 4). While phenobarbi-
tal exposure results in greater injury, the
liver's ability to respond by stimulated cell
division is not compromised, as evidenced
by the stimulation of hepatocellular
regeneration starting at 24 to 36 hr and
continuing through 72 hr. Therefore,
hepatocellular regeneration is stimulated
thereby counteracting the enhanced liver
injury, which leads to recovery from
increase in liver injury. In view of the
enhanced liver injury, restoration of nor-
mal hepatolobular architecture takes longer
than the approximately 24 hr required
upon administration ofa low dose ofCC14
alone. Although the hepatocellular regener-
ation is delayed from 6 to 24 hr, when it
does occur it is enhanced substantially,
apparently tempered by the demand for
more extensive restoration ofhepatolobular
architecture as a consequence of greater
injury (8,9,31). Hence, the overall effect of
phenobarbital-induced potentiation of
CC14 injury is merely to delay the stepped
up hepatocellular regeneration, tissue
repair, and restoration of hepatolobular
architecture. The prolongation of these
normal responses of the liver is a conse-
quence of the enhanced liver injury,
inflicted by the enhanced putative injurious
mechanisms. Interestingly, hepatic ATP
levels were only transiently decreased in
phenobarbital pretreated animals upon
administration of CC14 (27). Availability
ofcellular ATP at time points beyond 6 hr
permits a much stronger response through
much higher cell division at 24 hr.
CriticalRoleoftheEarly-Phase
Stimulation ofCelA Divisionand
TissueRepair
Table 5 presents a variety ofexperimental
manipulations that permit a rigorous
experimental verification of the existence
and the critical role of tissue repair in the
final outcome of toxic injury. The experi-
mental evidence for the existence of a
hormetic mechanism was derived as a result
ofefforts to understand the mechanism of
chlordecone potentiation of halomethane
toxicity.
Partial Hepatectomy. If the basic
premise is valid that suppression of the
early-phase (6 hr) stimulation ofcell divi-
sion and tissue repair is the mechanism of
chlordecone potentiation of CC14 injury,
then a preplacement ofcell division in the
liver should result in protection against the
interactive toxicity ofchlordecone + CC14.
When CC14 was administered 2 days after
partial hepatectomy at a time ofmaximally
stimulated hepatocellular division, a
remarkable protection was observed (43).
At 7 days after partial hepatectomy, when
the stimulated cell division phases out, the
interactive toxicity becomes fully mani-
fested again (43). In these studies, micro-
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Table 5. Experimental evidence supporting the proposed mechanism.
Experimental
manipulation
1. Preplaced cell division
and tissue repair by partial
hepatectomy.
2. Toxicity ofa large
dose of CC14.
3. Hepatocytes isolated from
chlordecone treated rats
incubated with CCI4.
(isolated hepatocytes
do not divide in vitro)
4. Developing young
rats have growing
livers.
5. a. Gerbils lackthe
early-phase tissue
repair.
5. b. Do not have early-
phase tissue repair
to suppress.
5. c. Preplaced tissue repair
by partial hepatectomy.
6. CCI4 autoprotection.
phase tissue repair bythe
protective dose.
7. a. Selective ablation of
the early-phase hormesis
by colchicine.
ensues to overcome injury).
7. b. Colchicine given 2 hr
before the protective dose
ofCC14.
Findings
Protection from chlordecone
+CCI4
Early-phase stimulation
oftissue repair is
ablated.
No potentiation in contrast to
in VIVO.
Chlordecone does not potentiate
toxicity.
a. Lowdose of CC14 is
highlytoxic
b. Resilientto chlordecone
potentiation of CCI4toxicity.
c. Resiliency to CCI4toxicity.
Due to prestimulation of early-
a. Prolongation of hepatotoxicity
of a low dose of CC14 by 24 hr (until
the second phase of cell division at
48 hr
b. Abolishes CCI4 autoprotection
entirely.
References
Kodavanti et al. (30,39,40)
Mehendale(41)
Kodavanti et al. (40);
Rao and Mehendale (45)
Mehendale et al. (46)
Cai and Mehendale (15,16)
Cai and Mehendale (15,16)
Cai and Mehendale (15,16)
Cai and Mehendale (48)
Thakore and Mehendale (49)
Rao and Mehendale (50,51)
Rao and Mehendale(52)
From Mehendale (44); reproduced with permission of Lewis Publishers.
somal cytochrome P450 content is
decreased by partial hepatectomy, but
remains at the decreased level even 7 days
later when protection is no longer evident.
Moreover, actual in vivo bioactivation, and
overall disposition of 14CC14 is unper-
turbed by partial hepatectomy (18).
Large Dose is Toxic Owing to the
Ablation ofthe Hormetic Response. An
implication of these findings is that the
toxic effect of a large dose of CC14 might
be a consequence ofsuppressed early-phase
cell division and tissue repair. When a large
dose ofCC)4 was administered, the early-
phase cell division normally stimulated by a
low dose of CC14 (20,21,31,40) was
ablated entirely (40,45,49). These findings
indicate that the real difference between a
low and a high dose ofCC14 is the presence
or absence of hormetic response in the
form ofstimulated early-phase cell division
and tissue repair. The higher dose clearly
prevents the hormetic response, thus per-
missively allowing toxicity to progress
unabatedly.
Interactive Toxicity ofChlordecone +
CCL4 Does Not Occur under In Vitro
Conditions Where Tissue Hormesis Can-
not be Expressed. Yet another line of
experimental validation of the critical role
ofsuppressed cell division and tissue repair
comes from in vitro incubation ofhepato-
cytes isolated from chlordecone pretreated
rats with CC14 (46). Isolated hepatocytes
do not divide under in vitro conditions.
Therefore, ifsuppression of cell division
and tissue repair ordinarily stimulated by a
low dose of CC14 is the mechanism of
chlordecone-amplified CC14 toxicity, one
should not observe highly amplified toxic-
ity when hepatocytes from chlordecone
treated rats are incubated with CC14 in
vitro. Since prior exposure to phenobarbital
is known to result in increased CC14 toxic-
ity in vitro, incubation of hepatocytes
obtained from phenobarbital treated rats
with CC14 should result in a measurable
level of increased toxicity. Such experi-
ments revealed no significant increase in
cytotoxic injury in chlordecone-pretreated
isolated hepatocyte incubations (46). Cells
from phenobarbital pretreated rats exhib-
ited highest CC14 toxicity indicating that
the in vitro paradigm was working as
expected. These findings are consistent
with the hypothesis that suppression of
hepatocellular division and tissue repair is
the primary mechanism of chlordecone-
potentiated CC14 toxicity, and provide sub-
stantial evidence against any significant role
for chlordecone-enhanced bioactivation of
CC14 (46).
Resiliency ofNewborn and Devel-
oping Rats. Newborn and young develop-
ing rats have actively growing livers. Since
livers during active growth would be
expected to have ongoing cefl division,
these developing rats would be expected to
be resilient during their early development.
When rat pups at 2, 5, 20, 35, 45, and 60
days were tested, rats were completely
resilient to chlordecone potentiation of
CC14 toxicity up to 35 days ofage (38,47).
At 45 days, young rats were sensitive to the
interactive toxicity of chlordecone + CC14
and by 60 days the rats were just as sensi-
tive as adults (47). The hepatic microso-
mal cytochrome P450 levels in the livers of
35-, 45- and 60-day-old rats exposed to
chlordecone were not different from each
other suggesting that any differences in
cytochrome P450 levels are unlikely to
explain the observed differences in toxici-
ties. Moreover, recent studies indicate that
bioactivation of 14CCI4 in 35-day-old rats
is not less than that observed in 60-day-old
rats (47). Therefore, the resiliency of
younger rats to chlordecone-potentiation
of CC4 toxicity is more likely related to
the ongoing hepatocellular regeneration
during early development rather than due
to differences in the bioactivation ofCC14.
Gerbils Lack the Early-Phase
Hormesis andAre Most Sensitive to
Halomethane Toxicity. While administra-
tion ofa low dose ofCC14 to rats results in
a prompt stimulation ofearly-phase hepa-
tocellular regeneration at 6 hr (30,31,
39,40,43), in Mongolian gerbils this early-
phase cell division is not observed (16).
The stimulation ofcell division which does
occur at 42 hr (analogous to the second
Volume 102, Supplement9, November 1994 143H.M. MEHENDALE
Table 6. High sensitivity of Mongolian gerbils to halomethane toxicity contrasted with their resiliency to potentia-
tion by exposure to other chemicals.
15-Day dietary pretreatment
Chlordecone, Phenobarbital, Mirex,
Halomethane Normal diet 10 ppma 225 ppma 10 ppma
CCI4 80 100 100 100
(34-186) (78-128) (28-354) (28-354)
CBrCI3 20 20 20 16.8
(8.6-46.5) (16.4-24.4) (10.4-38.4) (9.9-28.6)
CHCI3 400 565 400 400
(208-769) (346-923) (268-597) (268-597)
8pl/kg. "95% confidence intervals. From Cai and Mehendale (16); reproduced with permission of Archives of
Toxicology.
phase ofcell division which occurs at 48 hr
in rats) appears to be too little and too late
to be ofanyhelp in overcoming liver injury
(15,16). If the early-phase cell division is
critical for recovery from liver injury, then
owing to a lack ofthis important hormetic
mechanism in gerbils, they should be
extremely sensitive to halomethane toxic-
ity. When tested, gerbils were found to be
approximately 35-fold more sensitive to the
toxicity of CC14 (15). Likewise, gerbils
show several-fold greater sensitivity to the
lethal effects ofBrCCI3 and CHC13 (Tables
5,6). It follows that gerbils should not be
susceptible to chlordecone-potentiation of
CC14 toxicity (Table 6) since they lack the
early phase ofhepatocellular regeneration,
the target ofthat interaction (16). Studies
have shown that a preplacement ofhepato-
cellular regeneration by partial hepatec-
tomy results in significant protection
against CC14 toxicity (48), underscoring
the importance ofstimulated hepatocellular
regeneration in determining the final out-
come of liver injury. These studies also
reveal another important difference
between species. While rats respond by
maximal stimulation of hepatocellular
regeneration within 2 days after partial
hepatectomy, in gerbils the maximal stimu-
lation was many-fold lower and it occurs
not before 5 days after partial hepatectomy
(48). These findings indicate that gerbils
are much more sluggish in their hormetic
response to a noxious challenge of a hepa-
totoxic chemical agent. Each ofthese find-
ings points to the critical importance ofthe
early-phase stimulation ofcell division as a
decisive target of inhibition in chlorde-
cone-potentiation ofCC14 toxicity (Table
4). Secondly, these findings also underscore
the importance ofthe biological hormetic
response in determining the resiliency to
the toxic action ofhalomethanes.
Autoprotection. CC14 autoprotection is
a phenomenon, whereby administration of
a single low dose ofCC14 24 hr prior to the
administration ofa killing dose ofthe same
compound results in an abolition of the
killing effect of the large dose (49-57).
The widely accepted mechanism of this
phenomenon is the destruction of liver
microsomal cytochrome P450 by the pro-
tective dose such that subsequently admin-
istered large dose is insufficiently
bioactivated (32,58-62). Since bioactiva-
tion ofCC14 is an obligatory step for its
necrogenic action, it was suggested that
massive liver injury ordinarily expected
from a large dose ofCC14 never occurs in
the autoprotected animal (32). Although
this mechanism has been widely accepted, a
closer examination ofthe evidence suggests
that the mechanism was largely derived by
association (53-58) rather than actual
experimental evidence ofless than expected
liver injury in the autoprotected animal.
Additionally, several lines ofevidence indi-
cate that even after the significant destruc-
tion ofcytochrome P450, the availability
of the P450 isozyme responsible for the
bioactivation of CC14 is not limiting
(18,43,47,48,63,64). For instance, even
after a 60% decrease in the constitutive
liver microsomal cytochrome P450 by
CoCl2 treatment, CC14 toxicity was undi-
minished regardless ofwhether the rats
were pretreated with chlordecone (43).
More direct evidence was obtained from
studies in which in vivo metabolism and
bioactivation of14CCL4 were examined in
rats pretreated with CoCl2 (18). The
uptake, metabolism, and bioactivation of
CC14 were not significantly altered in
CoCl2 treated rats known to have highly
decreased liver microsomal cytochrome
P450 content.
Additional experimental evidence indi-
cating that actual liver injury observed in
rats receiving a high dose ofCC14 was iden-
tical regardless ofwhether prior protective
dose was administered led to a reexamina-
tion of the mechanism underlying CC14
autoprotection (49). A systematic time-
course study in which biochemical,
histopathological parameters as well as ani-
mal survival were examined revealed a criti-
cal role for the hormetic response of the
liver in the form ofstimulated early-phase
cell division and tissue repair (49). The
protective dose-stimulated tissue repair
results in augmented and sustained hepato-
cellular regeneration and tissue repair,
which enable the autoprotected rats to
overcome the same level of massive injury,
which is ordinarily irreversible and leads to
hepatic failure followed by animal death
(49,52).
SeketiveAblation ofthe Early-Phase
Hormetic Response by Colehicine. Finally,
the pivotal importance of the early-phase
stimulation ofhepatocellular division and
tissue repair was tested with an elegant
experimental tool, colchicine. With a care-
fully selected dose ofcolchicine, it was pos-
sible to selectively ablate the early-phase
stimulation of mitosis associated with the
administration of a low dose of CC14
(51,52). One single administration of
colchicine at 1 mg/kg results in ablation of
mitotic activity, the effect lasting only up
to 12 hr, such that the second phase ofcell
division at 48 hr after the administration of
CC14 is unperturbed (50). At this dose
colchicine does not cause any detectable
liver injury nor does it cause any adverse
perturbation of hepatobiliary function
(51). Therefore use ofcolchicine permits a
very important experimental paradigm in
which the early-phase hormesis in response
to a low dose ofCC14 can be selectively
ablated. The selective ablation ofthe early-
phase response ofcell division resulted in a
prolongation oflimited liver injury associ-
ated with a low dose of CC14 (50).
Ordinarily, ip administration of 100 pl
CCl4/kg results in very limited liver injury,
which is overcome by stimulated cell divi-
sion and tissue repair (20,21,30,31,
39,40,43), within 24 hr. The prolongation
ofthis limited injury lasts only for an addi-
tional 24 hr (up to 48 hr after CC14 injec-
tion) at which time the unperturbed
second phase ofcell division permits com-
plete recovery to occur within the next 24
hr (by 72 hr after CC14 injection). This
increased and prolonged CC14 injury is not
accompanied by enhanced bioactivation of
CC14 (50,52). Indeed, actual liver injury
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assessed by morphometric analysis or hepa-
tocellular necrosis and ballooned cells is
not enhanced during the first 12 hr in
colchicine treated rats, further indicating
that enhancement of the mechanisms
responsible for infliction ofinjury was not
responsible (50,52). These findings under-
score the pivotal role of the early-phase
stimulation ofhormesis in the final out-
come oftoxicity associated with a low dose
ofCC14.
Another experimental paradigm permits
a further test ofhow critical the early-phase
hormetic response is in the final outcome
of injury. In the above described experi-
ments, the preservation ofthe second phase
ofcell division permits complete recovery
by 72 hr. Administration ofa large dose of
CC14 permits one to experimentally inter-
fere with this second phase ofcell division.
In such an experiment, the animals should
not survive because ofcontinued progres-
sion of toxicity. In other words, selective
ablation of the early-phase hormetic
response in an autoprotection protocol
should result in a denial ofautoprotection.
Indeed, 100% survival observed in an
experimental protocol (100 pl CCl4/kg
administered 24 hr prior to the injection of
2.5 ml CCl4/kg) is completely denied by
colchicine antimitosis (52). This observa-
tion also provides very substantial and con-
vincing experimental evidence for the
newly proposed mechanism for the auto-
protection phenomenon (49,52). The
mechanism underlying the autoprotection
phenomenon is the ability ofthe liver tis-
sue to respond by augmentation of tissue
repair through hormesis induced by the
protective dose (49).
Two-StageModel ofToxicity
An intriguing outcome ofthe work on the
interactive toxicity ofchlordecone + CC14 is
the emergence ofa concept which permits
the separation ofthe early events responsi-
ble for infliction ofinjury from subsequent
events which determine the final outcome
ofthat injury (Figure 6). Hormetic mecha-
nisms (65) are activated upon exposure to
low levels of halomethanes (9,20,21,30,
31,39,66-68). Although the mechanisms
responsible for triggering a dramatic mobi-
lization of biochemical events leading to
cellular proliferation within 6 hr after expo-
sure to a subtoxic dose ofCC14 (9,22,30,
31,39) are not understood, it is clear that
these early events are the critical determi-
nants of the final outcome of injury
(1,33,41,42). When this early phase of
hepatocellular division is suppressed, as has
been observed in animals pretreated with
chlordecone (20,30,31,39), a permissive
and unabated progression ofliver injury
leading to massive coagulative hepatic
necrosis is observed (1,33,41,42). Likewise,
experimentally, it has been demonstrated
that restoring the tissue hormesis (Figure 7)
results in an obtundation ofthe progressive
phase of injury, permitting the tissue to
overcome injury.
The central role ofhormetic mecha-
nisms in the final outcome oftissue injury
becomes self-evident from the following
lines ofexperimental evidence. Prior expo-
sure to 225 ppm phenobarbital results in
the potentiation ofliver injury by the same
subtoxic dose of CC14 employed in the
chlordecone + CC14 interaction (1,2,4,31).
The quantitative measures ofliver injury at
24 hrafter the administration ofCC14indi-
cate that the tissue injury is either equiva-
lent to or slightly greater than that seen in
chlordecone + CC14 interaction (2). Left
alone, the animals undergoing the toxicity
of phenobarbital + CC14 combination
recover, while those experiencing the
chlordecone + CC14 combination do not
(1,4,33,41,42). While the enhanced liver
injury observed with the toxicity ofphe-
nobarbital + CC14 is consistent with the
increased bioactivation of CC14 (2,14),
recovery from this injury is consistent with
the unablated hepatocellular proliferation
and tissue repair (31,39). Delayed hepato-
Two - Stage Model Of Toxicity
Stage I Hormetic Mechanisms Recovery Active
Initiation and
Infliction of Injury
Stage 11
Hormetic Mechanisms Progression and
Inhibited Massive Injury
Chemicali ictioCellular Injury Massive Injury
Mechanisms Tissue Repair
Figure 6. Scheme illustrating the proposed two-stage model of toxicity. Stage involves infliction of cellular
and/or tissue injury by intoxication mechanisms, which are understood for many chemical and physical agents.
When injury is inflicted by a low dose ofthe offending agent(stage 1), hormetic mechanisms are stimulated (such
as cellular regeneration and tissue repair targeted for restoration of tissue structure) and complete recovery from
injury follows with no additional toxic consequence. If hormetic mechanisms are suppressed or ablated, the lim-
ited injury associated with exposure to a low dose ofthe offending toxic agentwould continue unabated resulting
in progressive injury. High doses oftoxic agents can cause ablation of the hormetic mechanism, as in the case of
high dose of CCI4, which results in ablation of the early-phase hormetic response (40). Another example is the
ablation of the early-phase hormesis exemplified by the interactive toxicity of chlordecone and the halomethane
solvents. From Mehendale (42); reproduced with permission of Lewis Publishers.
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Figure 7. Scheme illustrating the concept of separating those mechanisms which are responsible for the inflic-
tion of cellular and tissue injury from those which come to follow these events. Intoxication mechanisms result in
infliction of injury during stage of toxicity. During this stage tissue hormetic mechanisms are stimulated in an
attempt to overcome injury. If these hormetic mechanisms are unperturbed, recovery occurs. Interference with
these mechanisms results in uncontrollable progression of injury, resulting in stage 11 oftoxicity.
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cellular regeneration and tissue repair from
the normal 6 hr to 24 to 36 hr (1,31) is the
onlyconsequence on stage II ofCCI4 toxicity.
Nevertheless, the highly stimulated early
phase oftissue repair at 24 hr enables the
restoration ofhepatolobular structure and
function (1,33,41,42,44), and thereby animal
survival. These observations provide addi-
tional support for the concept of two dis-
tinct stages ofchemical toxicity (Figure 7).
Induction ofliver regeneration 36 to 48
hr after the administration ofa toxic dose
of CC14 is well established (69-71). The
existence ofan early phase ofcell division
(6 hr) was revealed only through experi-
ments with a low, subtoxic dose of CC14
(20,21,30,31). In fact, administration ofa
large, toxic dose ofCC14 (2.5 ml/kg) results
in complete suppression ofthis early phase
ofcell division (40,45,49), indicating that
the toxicity associated with a large dose is
due to the abolishment ofthis critical early
phase stimulation of tissue repair (1,33,
41,42). Therefore, it is possible to ablate
the early phase ofhepatocellular regenera-
tion and tissue repair ordinarily stimulated
by a low dose ofCC14, making it in essence
a toxic dose. Administration of the same
dose to animals prestimulated by partial
hepatectomy so that they have the ongoing
hepatocellular proliferation and tissue
repair, results in a remarkable and substan-
tial protection from liver injury and lethal-
ity (45). Likewise, administration of a
large lethal dose ofCC14 to animals receiv-
ing a smaller dose to stimulate cell division
and tissue repair results in complete protec-
tion (49,52). Such protection is not due to
decreased bioactivation ofCCl4 (18,50).
The importance of the stimulation of
tissue repair as an event independent of
stage I of chemical toxicity can be illus-
trated by other elegant experimental
approaches. Experimental interference with
the early phase ofhepatocellular prolifera-
tion leads to prolonged and enhanced liver
injury of an ordinarily subtoxic dose of
CC14. Studies with colchicine antimitosis
(50-52), wherein colchicine dose adminis-
tered selectively ablates the early phase of
hepatocellular division (6 hr) without
interfering with the second phase ofhepa-
tocellular regeneration (48 hr), have shown
a prolongation ofliver injury. Neither liver
injury measured through serum enzyme
elevations nor that measured by morpho-
metric analysis of necrosis was increased at
6 or 12 hr in colchicine treated rats, find-
ings consistent with the lack ofcolchicine-
enhanced bioactivation ofCC14 (50,52).
Moreover, colchicine ablation ofthe early-
phase hormetic response after the protec-
tive dose ofCC14 in an autoprotection pro-
tocol leads to complete denial ofautopro-
tection.
The critical role played by the capacity
to respond to CCl4-hepatotoxicity by stim-
ulation of tissue repair mechanisms at an
early time point is illustrated by examining
species and strain differences in susceptibil-
ity to CC14 injury. Mongolian gerbils are
extremely sensitive to halomethane hepato-
toxicity (15,16,48,72). Gerbils are approxi-
mately 35-fold more sensitive to CC14
toxicity than Sprague-Dawley rats (15,16).
This difference in CC14 toxicity can be
seemingly explained on the basis ofa 3.5-
fold greater bioactivation ofCC14 in gerbils
(15). However, the remarkable and sub-
stantial sensitivity does not appear to be
due to 3.5-fold greater bioactivation of
CC14, since CC14 toxicity is not at all
increased in gerbils by prior exposure to
phenobarbital in spite ofa 5-fold greater
bioactivation ofCC14-(15,16). The time-
course studies on the ability ofgerbils to
respond to a subtoxic dose of CC14 by
stimulation ofhepatocellular regeneration
and tissue repair reveal an important differ-
ence in the biology ofthe hormetic mecha-
nisms between gerbils and rats (16). The
early-phase stimulation of tissue repair in
the liver does not manifest itself in gerbils
and the second phase occurs approximately
40 hr after the administration of CC14
(16,48). In the absence of the biological
mechanism to arrest the progression of
liver injury (Figure 7), the liver injury
might be expected to permissively progress
much like an unquenched brushfire.
Evidence in support ofthe concept that
species differences in chemical toxicity
might depend on the differences in the
promptness in initiating tissue repair mech-
anisms among various species comes from
another aspect ofthe interactive toxicity of
chlordecone + CC14. While gerbils are
extremely sensitive to CC14, this sensitivity
cannot be further increased by prior expo-
sure to chlordecone (15,16,48,72). Since
substantial evidence supports the concept
that suppression ofthe early phase ofhepa-
tocellular regeneration and tissue repair is
the mechanism for the permissive progres-
sion of liver injury in the chlordecone +
CC14 interaction (1,33,41,42,44), lack of
this early phase response in the gerbil
would be consistent with extremely high
sensitivity of gerbils to CC14 on the one
hand, and a lack ofpotentiation of CC14
toxicity by prior exposure to chlordecone
on the other (15,16). This concept has
received additional support through partial
hepatectomy experiments (48).
The toxicity of chlordecone + CHCl3
combination has been demonstrated in
murine species (6-9). Stimulation ofhepa-
tocellular regeneration and tissue repair
after a subtoxic dose ofCHCl3 allows the
mice to overcome the liver injury associ-
ated with that dose ofCHCl3 (9). By low-
ering the dose of CHCl3 used in the
chlordecone + CHCl3 studies (8), it is possible
to demonstrate potentiation ofliver injury,
butwithout the lethality (9). Such an experi-
mental protocol vividly reveals a decisive
role played by the stimulated tissue repair
mechanisms in overcoming liver injury (9)
and the separation of these mechanisms
(stage II) from the inflictive phase (stage I)
ofchemical injury (Figure 7).-
The importance of stimulated tissue
repair mechanisms in overcoming liver
injury has also been demonstrated through
examination of the mechanistic basis for
significant strain differences in mice
(73,74). An SJL/J strain ofmice, known to
be least susceptible to CC4 toxicity, was
shown to possess more prompt and effi-
cient tissue repair mechanisms, which per-
mit augmented recovery, while the
BALB/C strain, known to be more suscep-
tible, was shown to possess less efficient tis-
sue repair mechanisms resulting in slow
recovery (73). The F, cross between these
two strains was shown to be intermediate
in susceptibility (74). A careful histopatho-
logical evaluation revealed that while the
time course ofthe appearance ofinjury was
quite similar (stage I, Figure 6), significant
differences in tissue repair mechanisms
between these strains could account for the
strain differences in CCd4 toxicity (73,74).
While the time course of the inflictive
phase ofinjury in the F1 (SJL/J x BALB/C)
was similar to the two parent strains, the
tissue repair was at the intermediate level of
augmented (SJL/J) and retarded (BALB/C)
recovery.
With the advent of the finding that a
low dose ofCC14 is not toxic, not so much
because it does not initiate tissue injury,
but because ofthe stimulated tissue repair
mechanisms (44), it became apparent that
the stimulation ofthe early phase ofhepa-
tocellular regeneration is in essence an
endogenous hormetic mechanism,
recruited to overcome tissue injury. One
implication of this finding is its possible
role in the phenomenon ofCC14 autopro-
tection (53-55,60). Circumstantial evi-
dence, wherein hepatic microsomal
cytochrome P450 was decreased by CoCl2
administration to 40% ofthe normal level
did not result in decreased CC14 liver
injury (43), suggested the possibility that
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mechanism(s) other than decreased
cytochrome P450 might be involved in
CC14 autoprotection. Recent studies reveal
a critical role for the hepatocellular regener-
ation and tissue repair stimulated by the
low protective dose administration (49).
Essentially, the protective dose serves to
stimulate tissue repair mechanisms
(18,20,21,30,39) so that even before the
large dose known to abolish the early phase
stimulation oftissue repair (40) is adminis-
tered, the tissue repair mechanisms are
already in place, resulting in augmentation
of tissue repair sufficient to tip the balance
between injury and recovery in favor ofthe
latter (49). This experimental model repre-
sents another example wherein a selective
augmentation ofthe tissue hormetic mech-
anism (stage II, Figure 6) independent ofthe
inflictive phase oftoxicity (stage I, Figure
6), one can dramatically alter the ultimate
outcome oftoxic injury (Figure 7).
Another line of evidence to implicate
the importance of the hormetic mecha-
nisms in determining the final outcome of
chemical toxicity comes from experiments
designed to understand the mechanisms
responsible for the failure of the tissue
regenerative and repair mechanism in the
interactive toxicity of chlordecone + CC14.
Much evidence is available to implicate
insufficient availability ofcellular energy at
a time when cell division should have taken
place (20,21,75). A remarkable and irre-
versibly precipitous decline in glycogen lev-
els in the liver (21,26), a rise in
hepatocellular Ca2+ (22-25), a consequent
stimulation of phosphorylase a activity,
leading to an equally precipitous decline in
hepatic ATP (26,27), are events consistent
with the failure ofhepatocellular regenera-
tion in the chlordecone + CC14 interaction.
Only marginal and transient decline in
ATP levels in the interactive hepatotoxicity
ofphenobarbital + CC14 and mirex + CC14
(28) are consistent with only a postpone-
ment ofhepatocellular regeneration leading
to transiently increased liver injury fol-
lowed by complete recovery (31). The con-
cept of insufficient hepatocellular energy
being linked to failure of hepatocellular
regeneration and tissue repair has gained
support from experiments in which the
administration ofexternal source ofenergy
resulted in augmented ATP levels and sig-
nificant protection (28,29,45). Catechin
(cyanidanol), known to increase hepatic
ATP levels, protects against the lethal effect
ofchlordecone + CC14 (28,29). Protection
by catechin is accompanied by a restored
stimulation ofhepatolobular repair and tis-
sue healing (29). The most interesting
Table 7. Chemicals reported to cause nonneoplastic
hepatocellular proliferation.
Chemicals References
1. Acetaminophen Zieve et al. (76)
2. Allyl alcohol Zieve et al. (76,77)
3. ax-Naphthyl isothiocyanate McClean and Rees (78)
Ungar et al. (79)
4. Bromotrichloromethane Faroon and
Mehendale(66)
5. Carbon tetrachloride Lockhart et al. (20,21)
Nakata et al. (71)
6. Chloroform Condie et al. (80)
7. Ethylene dibromide Natchomie and
Farber(81)
8. Galactosamine Lesch et al. (82)
Kuhlmann and
Wurster(83)
9. Thioacetamide Gupta (84)
Reddy et al. (86)
aspect of catechin protection against the
interactive toxicity ofchlordecone + CC14
is that protection does not appear to be the
result of decreased infliction of hepatic
injury (28,29), as evidenced by a lack of
difference in injury up to 24 hr after CC14
administration (29). These observations
provide substantial evidence for the separa-
tion ofstage I oftoxicity responsible for the
infliction of tissue injury from the stage II
events responsible for the final outcome of
tissue injury (42).
Abundant opportunities are available to
test the two-stage ofmodel toxicity. Many
chemicals have been reported to induce
hepatocellular regeneration at relatively
modest doses, some ofwhich are listed in
Table 7. Opportunities to test the concep-
tual framework being put forth here are
available through additional investigations
with these models oftissue injury as well as
scores ofother models in other tissues and
organs.
Implicationsfor Assessment
of Riskto Public Health
Establishing that the initial toxic or injuri-
ous events, regardless of how they are
caused, can be separated from the subse-
quent events that determine the ultimate
outcome ofinjury, offers promising oppor-
tunities for developing new avenues for
therapeutic intervention with the aim of
restoring the hormetic tissue repair mecha-
nisms. Such a development will open up
avenues for two types of measures to pro-
tect public health. The presently used prin-
ciple is to decrease injury by interfering
with stage I of toxicity by treatment with
an antidote, which either prevents further
injury or decreases already inflicted injury.
The second, wherein tissue repair and heal-
ing mechanisms could be enhanced not
only to obtund the progression of injury,
but also to simultaneously augment recov-
ery from that injury, is a novel approach.
In addition to these opportunities, the
two-stage concept ofchemical toxicity also
embodies implications ofsignificant inter-
est in the assessment of risk from exposure
to toxic chemicals. The existence of a
threshold for chemical toxicity is evident as
indicated by the stimulation oftissue repair
mechanism directed to tissue healing and
recovery observed after the administration
ofsubtoxic levels oftoxic chemicals, when
exposure involves singular chemicals. The
existence ofa two-level or two-stage thresh-
old is apparent from the two-tier hormetic
response: one threshold for each stage of
the two-stage model. Generally speaking,
the threshold for stage I oftoxicity must lie
in the cytoprotective mechanisms (cellular
hormesis). The threshold for stage II of
toxicity appears to be in the tissue's ability
to respond promptly by augmenting tissue
healing mechanisms. These thresholds may
be quantitatively the same or different.
From a public health perspective, expo-
sure to singular chemicals is seldom
involved. Multiple exposures to chemical
combinations and solidus or singular com-
ponents simultaneously, intermittently, or
sequentially are almost always the rule. In
this regard, antagonistic interactive toxicity
or inconsequential interactions are also of
interest. Ofgreater interest from a public
health perspective, is the finding that the
hormetic mechanisms which constitute the
threshold for physical or chemical toxicity
can be mitigated by other chemical and
physical agents, resulting in highly accentu-
ated toxicity.
Ofsignificantly greater interest is the
need to take into account the hormetic
mechanisms operating particularly at the
low levels ofexposure to chemicals, in the
assessment of risk from exposures to com-
binations of chemicals at low doses. The
recognition of the existence ofcellular and
tissue hormesis provides a mechanistic basis
to recognize thresholds for toxic effects,
thereby permitting us to take into consid-
eration the lack of recognizable adverse
health effects at low levels of exposure to
chemicals in our environment.
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